Entering text into the input field will update the search result below

Acadia Pharmaceuticals (NASDAQ:ACAD) soars 51% after saying that the results of a Phase III...

Acadia Pharmaceuticals (NASDAQ:ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR)

Recommended For You

About ACAD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACAD--
ACADIA Pharmaceuticals Inc.